Drug Profile
Zampilimab - UCB
Alternative Names: UCB 7858Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator UCB
- Developer Chiesi; UCB
- Class Anti-inflammatories; Antibodies; Monoclonal antibodies
- Mechanism of Action Transglutaminase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Renal failure
- Research Idiopathic pulmonary fibrosis
- No development reported Autoimmune disorders
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in United Kingdom (IV, Infusion)
- 04 May 2022 UCB Biopharma terminates phase I/II trial in Renal failure in Australia, Beligium, Spain and the UK due to recruitment challenges (NCT04335578; EudraCT2017-004807-31)
- 01 Dec 2021 Early research in Idiopathic pulmonary fibrosis in Belgium (Parenteral)